Diabetic cardiomyopathy (DCM) is a distinct myocardial complication of diabetes, characterized by early diastolic dysfunction, progressive fibrosis, and eventual heart failure. Clinical metabolomics studies have identified disruptions in amino acid metabolism and arachidonic acid pathways in patients with DCM, with metabolites such as 5-OxoETE and D-Glutamine showing strong diagnostic potential. These circulating biomarkers not only offer promise for early detection of subclinical myocardial dysfunction but also provide mechanistic insights that could guide novel therapeutic strategies in diabetes-related cardiac disease.
To read more, Click here Are metabolomic biomarkers the bridge to precision care in DCM? ##Reference## Li, Jialong, et al. "Identification of metabolic pathways and serum biomarkers in diabetic cardiomyopathy using untargeted metabolomics." Scientific Reports 15.1…
